News
IRON
79.23
-0.18%
-0.14
5 Reasons To Buy Clinuvel Pharmaceuticals After Its Nasdaq Uplisting
Seeking Alpha · 3d ago
Disc Medicine Price Target Raised to $100.00/Share From $88.00 by Wedbush
Dow Jones · 3d ago
Disc Medicine Is Maintained at Outperform by Wedbush
Dow Jones · 3d ago
Wedbush Maintains Outperform on Disc Medicine, Raises Price Target to $100
Benzinga · 3d ago
Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON), Eli Lilly & Co (LLY) and Rocket Pharmaceuticals (RCKT)
TipRanks · 4d ago
Disc Medicine To Present Data From Multiple Clinical Programs At The SOHO Annual Meeting, To Be Held In Houston, Texas, On September 9-12, 2026
Benzinga · 4d ago
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
Barchart · 4d ago
Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Barchart · 5d ago
Weekly Report: what happened at IRON last week (0824-0828)?
Weekly Report · 5d ago
Disc Medicine: Buy Rating Reiterated on Undervalued Hematology Pipeline, Upcoming Clinical Catalysts, and Unchanged $100 Price Target
TipRanks · 08/27 20:45
Disc Medicine (IRON): Betting On Iron And Heme Biology
NASDAQ · 08/27 06:11
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
Barchart · 08/26 18:24
Weekly Report: what happened at IRON last week (0817-0821)?
Weekly Report · 08/24 09:10
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
PR Newswire · 08/22 17:32
Disc Medicine price target raised to $90 from $85 at Morgan Stanley
TipRanks · 08/17 13:05
Weekly Report: what happened at IRON last week (0810-0814)?
Weekly Report · 08/17 09:10
Disc Medicine (IRON) Gets a Buy from Wedbush
TipRanks · 08/11 13:55
Analysts Conflicted on These Healthcare Names: CVRx (CVRX), Jazz Pharmaceuticals (JAZZ) and Disc Medicine (IRON)
TipRanks · 08/11 13:40
H.C. Wainwright Sticks to Its Buy Rating for Disc Medicine (IRON)
TipRanks · 08/10 10:55
Weekly Report: what happened at IRON last week (0803-0807)?
Weekly Report · 08/10 09:09
More
Webull provides a variety of real-time IRON stock news. You can receive the latest news about Disc Medicine Inc through multiple platforms. This information may help you make smarter investment decisions.
About IRON
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.